|Over a week ago|
Nuvation Bio participates in a conference call with Jefferies » 11:1804/1904/19/21
Healthcare Analyst Yee…
Healthcare Analyst Yee holds a conference call with management on April 19 at 12 pm hosted by Jefferies.
|Over a month ago|
Fly Intel: Top five analyst initiations » 09:5304/0604/06/21
MCD, YUM, SBUX, YUMC, GNOG, CELH, YETI, NUVB
Catch up on today's…
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. McDonald's (MCD) and Yum! Brands (YUM) initiated with a Neutral at Atlantic Equities, with Starbucks (SBUX) and Yum China (YUMC) initiated with an Overweight at Atlantic Equities. 2. Golden Nugget Online (GNOG) initiated with a Buy at Jefferies. 3. Celsius Holdings (CELH) initiated with a Neutral at Credit Suisse. 4. Yeti (YETI) initiated with an Outperform at Credit Suisse. 5. Nuvation Bio (NUVB) initiated with an Outperform at RBC Capital. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
Nuvation Bio initiated with an Outperform at RBC Capital » 08:2004/0604/06/21
RBC Capital analyst Mark…
RBC Capital analyst Mark Dwelle initiated coverage of Nuvation Bio with an Outperform rating and $15 price target. The analyst is positive on the company's "strong" management team and capital position, which should enable its "expeditious" development of its novel anti-cancer agent pipeline with key phase 1 catalysts approaching at the end of 2021 and in 2022. Nuvation's lead asset NUV-422 offers a "differentiated" potential best-in-class agent based on brain penetrance and improved target exposure, Dwelle tells investors in a research note.
Nuvation Bio files to sell 60.9M shares of common stock for holders 17:1103/1103/11/21
Nuvation Bio announces FDA orphan drug designation for NUV-422 » 07:0403/1103/11/21
Nuvation Bio announced…
Nuvation Bio announced that the U.S. FDA has granted Orphan Drug Designation to NUV-422, a cyclin-dependent kinase 2/4/6 inhibitor, for the treatment of patients with malignant gliomas.
Nuvation Bio initiated with a Buy at Jefferies » 08:0903/0803/08/21
Jefferies analyst Michael…
Jefferies analyst Michael Yee initiated coverage of Nuvation Bio with a Buy rating and $20 price target. The company has "elegant chemistry in multiple high-value cancer area," said Yee, who notes Nuvation has five different cancer programs all with data over the next few years. The company's NUV-422 is "a differentiated and improved" CDK 2/4/6 for glioblastoma and breast cancer that "could move fast," said Yee, who adds that Nuvation may file up to five Investigational New Drug applications over the next six years.
Nuvation Bio initiated with an Outperform at Cowen » 07:3603/0803/08/21
Cowen analyst Yaron Weber…
Cowen analyst Yaron Weber initiated coverage of Nuvation Bio with an Outperform rating. The analyst said its proven management team is building a deep pipeline focusing on novel and validated oncogenic pathways. He anticipates development for mBC and patients with brain metastases and with a deep pipeline poised for Five INDs in six years, he is bullish on the shares.
Wedbush bullish on Nuvation Bio, initiates with an Outperform » 07:2303/0803/08/21
As previously reported,…
As previously reported, Wedbush analyst David Nierengarten initiated coverage of Nuvation Bio with an Outperform rating and $20 price target. The analyst notes that the company's lead program NUV-422 is a cyclin-dependent kinase 2/4/6 inhibitor currently in a Phase 1/2 study for recurrent/refractory high-grade gliomas. Initial data from the Phase 1 portion of the study are expected in 2022 and Nuvation Bio intends to initiate additional studies for the program throughout 2022 including in brain metastases, ER-positive metastatic breast cancer, and metastatic castrationresistant prostate cancer, he adds. Nierengarten projects the program could achieve over $3B in worldwide revenues by 2028 assuming success.
Nuvation Bio initiated with an Outperform at Wedbush » 06:2903/0803/08/21
Wedbush initiated coverage of Nuvation Bio with an Outperform rating and $20 price target.
Nuvation Bio initiated with a Buy at BTIG » 05:4503/0803/08/21
BTIG analyst Thomas…
BTIG analyst Thomas Shrader initiated coverage of Nuvation Bio with a Buy rating and $16 price target. Nuvation is a clinical-stage oncology company with multiple small molecule drug candidates designed to improve on standard of care regimens via more precise targeting, Shrader tells investors in a research note.